ILiAD Biotechnologies leads this week’s round-up of new private financings in the biopharma sector, with a $115 million Series B investment that will be used to test a new type of whooping cough (Bordetella pertussis) vaccine.The Florida, US biotech’s BPZE1 candidate is a live, attenuated pertussis vaccine delivered as an intranasal formulation, licensed by ILiAD […]
